de Angelis Cristina, Frantellizzi Viviana, Pontico Mariano, de Feo Maria Silvia, Lazri Julia, de Vincentis Giuseppe
Sapienza University of Rome, Department of Radiological Sciences, Oncology and Anatomical Pathology, Rome, Italy
apienza University of Rome, Ph.D. Program in Morphogenesis and Tissue Engineering, Department of Medico-surgical Sciences and Biotechnologies, Rome, Italy
Mol Imaging Radionucl Ther. 2021 Oct 15;30(3):193-196. doi: 10.4274/mirt.galenos.2020.58661.
There have been several studies on the clinical outcomes of Radium-223 treatment in patients with metastatic castration-resistant prostate cancer (mCRPC) who may have an increased risk of hematologic comorbidities. To the best of our knowledge, this is the first study to explore the potential bone marrow adverse effects (AEs) of Radium-223 administered with specific drugs used for hematologic conditions, such as polycythemia vera (PV). We report the case of a patient with mCRPC who was administered a combined treatment of Radium-223 and hydroxyurea for PV, aiming to support clinicians in predicting eventual AEs.
已有多项关于镭-223治疗转移性去势抵抗性前列腺癌（mCRPC）患者临床结局的研究，这些患者可能有血液系统合并症风险增加的情况。据我们所知，这是第一项探索镭-223与用于血液系统疾病（如真性红细胞增多症（PV））的特定药物联合使用时潜在骨髓不良反应（AE）的研究。我们报告了一例mCRPC患者，该患者接受了镭-223和羟基脲联合治疗PV，旨在帮助临床医生预测最终的AE。
